|   |   | 
Legal status
Patent not validated
| (51) | INT.CL. | C07D 215/58 | |
| C07D 215/227 | |||
| A61K 31/47 | |||
| A61K 31/198 | |||
| A61P 37/08 | 
| (11) | Number of the document | 2337779 | 
| (13) | Kind of document | T | 
| (96) | European patent application number | 09812145.2 | 
| Date of filing the European patent application | 2009-09-02 | |
| (97) | Date of publication of the European application | 2011-06-29 | 
| (45) | Date of publication and mention of the grant of the patent | 2017-04-19 | 
| (46) | Date of publication of the claims translation | 
| (86) | Number | PCT/US2009/055692 | 
| Date | 2009-09-02 | 
| (87) | Number | WO 2010/028015 | 
| Date | 2010-03-11 | 
| (30) | Number | Date | Country code | 
| 93943 P | 2008-09-03 | US | 
| (72) | 
                    
                    
                    
                    
                    GANT, Thomas G., US  
                    
                    
                    
                    
                    SHAHBAZ, Manouchehr M., US  | 
| (73) | Teva Pharmaceutical Industries Ltd.,
                5 Basel Street  P.O. Box 3190, 49131 Petach-Tikva,
                IL | 
| (54) | 2-OXO-1,2-DIHYDRO-QUINOLINE MODULATORS OF IMMUNE FUNCTION | 
| 2-OXO-1,2-DIHYDRO-QUINOLINE MODULATORS OF IMMUNE FUNCTION |